Nov 15, 2022 / 07:00AM GMT
Britt Meelby Jensen - Ambu A/S-CEO&Member of Management Board
So good morning, everyone. Very nice to have you on this call this morning for Ambu's Q4 and full year results as well as our strategy update. I'm Britt Meelby Jensen, the CEO of Ambu. And this morning, I'm here with Thomas Frederik Schmidt, our Chief Financial Officer; and Bassel Rifai, our Chief Marketing Officer.
So we will, in the agenda today, first go through our financial results and key events from the year that we have just closed. After that, we'll provide an update on our strategy, and we'll finish the call with a Q&A session.
So looking back at the past year, it has been an eventful year for Ambu. Our 2 main new products, cystoscope and our rhinolaryngoscope, have had a very good year selling over 700,000 scopes in the year.
Also, we have had 2 major launches towards the end of last fiscal year, the aScope 5 Bronchoscope and our gastroscope, which I'll come back and provide an update on later today.
Also during the year, we have expanded
Q4 2022 Ambu A/S Earnings Call Transcript
Nov 15, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers